Methylglyoxal-AGE (Arg-Pyrimidine)Catalog number: AGE06B
The antibody 6B is suitable for the detection of MG-derived AGE especially of Arg-Pyrimidine in tissues and tissue extracts. Special focus will be put on the investigation of arterial sclerosis and protein deposits in the brain, renals, retina and lens. Methylglyoxal (MG) is a cytotoxic metabolite, which is synthesized as a side product of glycolysis. In diabetic hyperglycaemia accumulation of MG and irreversible binding to cellular proteins especially Arg- and Lys-residues may occur. This leads to the formation of "Advanced Glycation End Products" (AGE). The formation of MG-derived AGE contributes to several pathological conditions including artherosclerosis, Alzheimer's disease and complications in diabetes (blindness, neuropathy, nephropathy). The glyoxalase-1-system (GLO1) is stimulated in different tumours (Colon-, Mamma- and Prostate-Ca) and correlates with the very fast formation of MG-adducts in TNF-stimulated Apoptosis. This leads to the conclusion that in those cases AGE products are formed through enzymatic reactions. Methylglyoxal (MG)-Adducts, primarily Arg-Pyrimidine (N?-(4-Carboxy-4,6-Dimethyl-5,6-Dihydroxy-1,4,5,6-Tetrahydropyrimidine-2-yl)-L-Ornithine), cross-reactivity with Tetrahydropyrimidine and 5-Hydro-5-Methylimidazolone app. 0.1% in ELISA, Immidazolysine and (Carboxyethyl)lysine <0.1%.
Antibody purified by ammonium sulphate from ascites, taken up in 10 mM PBS; 0.5% BSA; 0.1% NaN3
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art. No. AE005).
Concentration: 100 µg/ml
Species Reactivity: Human
IHC(C, P), WB
Incubation Time: 60 min at RT or 18 hr at 2-8°C
Working Concentration: (liquid conc.) 1 µg/ml
Positive Control: nephropathic renal tissue
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Oya T., Hattori N., Mizuno Y., Miyata S., Maeda S., Osawa T., and K. Uchida (1999) Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J. Biol. Chem. 274(26); 18492-18502. 2. Van Herreweghe F., Mao J., Chaplen F.W.R., Grooten J., Gevaert K., Vandekerckhove J., and K. Vancompernolle (2002) Tumor necrosis factor-induced modulation of glyoxalase 1 acticvities through phosphorylation by PKA results in cell death and is accompan 3. Shipanova I.N., Glomb M.A., and R.H. Nagaraj (1997) Protein Modification by Methylglyoxal: Chemical nature and synthetic mechanism of a major fluorescent adduct. Arch. Biochem. Biophys.344(1); 29-36. 4. Padayatti P.S., Ng A.S., Uchida K., Glomb M.A., and R.H. Nagaraj (2001) Argpyrimidine, a blue fluorophore in human lense proteins: high levels in brunescent cataractous lenses. Invest Ophthalmol. Vis. Sci. 42(6); 1299-1304. 5. Padayatti P.S., Jiang C., Glomb M.A., Uchida K., and R.H. Nagaraj (2001) High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells. Curr. Eye Res. 23(2); 106-115.
Safety Datasheet(s) for this product: